评估基于免疫组化亚型和治疗方案的非转移性炎症性乳腺癌的真实世界结果和预后因素。对2001年至2018年诊断为III期炎症性乳腺癌的患者进行了机构性的回顾性分析，这些患者接受了新辅助系统治疗（NAST）治疗。分析了与患者特征、肿瘤特征、治疗方式和对NAST的反应有关的存活结果。225名患者符合纳入标准，其中90%的患者为淋巴结阳性。免疫组化亚型：39.1%为HR + / HER2-，19.1%为HR + / HER2 +，23.1%为HR- / HER2 +，18.7%为HR- / HER2-。治疗是多模式的：NAST（100％），手术（94.2％）和放射治疗（94.2％）。53.3％的患者接受了辅助内分泌治疗，34.3％（新）辅助曲妥珠单抗。 89.3%的患者采用三联疗法。在NAST后，16.9％的患者在乳房中发现病理完全缓解（pCR），29.7％的患者在腋窝中发现pCR，并且10.3％的患者在乳房和腋窝中均发现pCR。腋窝pCR率在HR-亚型中显著较高。基于免疫组化的亚型中位总生存期（OS）分别为8.9、7.2、5.8和2.3年（P <0.001），分别为HR + / HER2-、HR + / HER2 +、HR- / HER2 +和HR - / HER2-亚型。多元分析显示，基于免疫组化的亚型、年龄和腋窝pCR是RFS和OS的独立预后因素。pCR率和中位OS随时间改善，分别为5.8％对14.7％和4.7 vs 10.0年（2001-2009 vs 2010-2018）。腋窝pCR和非三阴性基于免疫组化的亚型是炎症性乳腺癌RFS和OS有利的预后因素。紫杉醇和抗HER2药物的引入有助于改善pCR率和OS。版权所有©2023年作者。由Elsevier Ltd.出版。保留所有权利。

To assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer according to immunohistochemistry (IHC)-based subtype and treatment regimen.An institutional retrospective analysis of patients treated with neoadjuvant systemic treatment (NAST) for stage III inflammatory breast cancer diagnosed between 2001 and 2018 was performed. The survival outcomes in relation to patient characteristics, tumour characteristics, treatment modality and response to NAST were analyzed.225 patients fulfilled the inclusion criteria, 90% of patients were node-positive. IHC-based subtypes: 39.1% were HR+/HER2-, 19.1% HR+/HER2+, 23.1% HR-/HER2+ and 18.7% HR-/HER2-. Treatment was multimodal: NAST (100%), surgery (94.2%) and radiotherapy (94.2%). 53.3% of patients received adjuvant endocrine therapy, 34.3% (neo)adjuvant trastuzumab. Tri-modality therapy was applied in 89.3% of patients. Following NAST, a pathologic complete remission (pCR) in the breast was found in 16.9%, in the axilla in 29.7% and in both the breast and axilla in 10.3% of patients. The axillary pCR rate was significantly higher in HR- subtypes. Median overall survival (OS) was 8.9, 7.2, 5.8 and 2.3 years (p < 0.001) for HR+/HER2-, HR+/HER2+, HR-/HER2+ and HR-/HER2- subtype, respectively. On multivariate analysis, IHC-based subtype, age and axillary pCR were found as independent prognostic factors for RFS and OS. pCR rate and median OS improved over time, 5.8% vs 14.7% and 4.7 vs 10.0 years (2001-2009 vs. 2010-2018), respectively.Axillary pCR and the non-triple-negative IHC-based subtype are favourable prognostic factors for RFS and OS in inflammatory breast cancer. Introduction of taxanes and antiHER2 drugs contributed to improved pCR rate and OS.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.